Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award

Williams, Corinne L.

doi:10.1172/jci90179

Cited by 4 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another start-up, Apath LLC, was founded by Charles Rice (Rockefeller University and Washington University) that focused on licensing technology to pharmaceutical companies to develop products to treat HCV. Rice and his team were also working on developing technology to culture HCV, and were successful 37 , 38 , 39 . In 2005, other teams also grew HCV in the laboratory, including researchers at the National Institute of Diabetes and Digestive and Kidney Diseases, Rockefeller University, Scripps Research Institute, and possibly others 14 , 40 , 41 , 42 .…”

Section: Resultsmentioning

confidence: 99%

Public funding for transformative drugs: the case of sofosbuvir

Barenie

Avorn

Tessema

et al. 2021

Drug Discovery Today

View full text Add to dashboard Cite

Highlights Transformative drugs often emerge from investment by public and private actors. Sofosbuvir changed hepatitis C care, but had public support through NIH. An estimated $60.9 million in public dollars supported sofosbuvir’s development. Government investment in drug development should be reflected in price and access.

show abstract

Section: Resultsmentioning

confidence: 99%

Public funding for transformative drugs: the case of sofosbuvir

Barenie

Avorn

Tessema

et al. 2021

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…His fundamental area of interest is the HCV replication cycle's molecular and cellular underpinnings. Simultaneously, he is associated with the German Cancer Research Center[ 29 ]. Charles M. Rice and Ralf Bartenschlager are globally acknowledged for their contributions to HCV research.…”

Section: Discussionmentioning

confidence: 99%

Analysis of articles on hepatitis C by scientific mapping: 1989-2022

Tok

2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Hepatitis C virus (HCV) poses a significant quandary about public health. It is challenging to study the literature in a particular discipline comprehensively today. One solution is bibliometric analysis, which is often used to track the attributes and evolutionary trajectories of scientific outputs. AIM To examine the 35-year scientific evolution of articles focused on HCV. METHODS This study examined the 35-year scientific evolution of articles focused on HCV. Our study utilized the Web of Science database. The study encompassed a total of 11930 articles. RESULTS Regarding the cumulative count of articles, the leading countries are the United States, Japan, and Italy. Rice CM is the author with the highest recorded H-index and G-index values. The journal with the highest recorded H-index and G-index values is the Journal of Virology . The Journal of Viral Hepatitis contributed 10.94% of the articles, whereas the Journal of Virology published 9.68%. According to the strategic diagram, the keywords most frequently used in 2020-2022 are HCV, epidemiology, and sofosbuvir. CONCLUSION This study provides valuable information about 40 years of academic knowledge on HCV.

show abstract

“…The identification of cell culture-adaptive mutations that confer a drastic increase in HCV replication level was a gateway to the establishment of high replicative subgenomic replicons 72 that paved the way for drug discovery and testing. 73,74 As HCV exhibits a 20%-25% divergence at the subtype level, 10 an unmet need to develop subgenomic replicon (SGR) for each subtype exists. The current existence of SGRs systems for only three GT4 subtypes exemplifies this.…”

Section: Hcv Subgenomic Repliconmentioning

confidence: 99%

“…Over time, the HCV basic research field has witnessed several landmark achievements, including the early virus discovery, which was acknowledged with the 2020 Nobel Prize 92 and the 2000 Lasker award 93 as well as the later development of replicon system and high effective DAA, which received the 2016 Lasker award. 73,74 Even though the introduction of these antiviral drugs in 2011 has revolutionized HCV therapy, increasing the SVR rate to over 90%, 94 early generations of these compounds were mainly developed to target GT1, whose resistant-associated substitutions have mainly been studied. 95 The recent approval of pan-genotypic antiviral combinations has helped broaden the spectrum of activity to many other genotypes and subtypes (GT1a, GT1b, and GT3a), mostly present in the developed world.…”

Section: Challenges and Perspectivesmentioning

confidence: 99%

“…The introduction of such bicistronic RNA into human hepatoma cells followed by G418 selection, results in the production of stable cells weakly replicating the HCV RNA. The identification of cell culture‐adaptive mutations that confer a drastic increase in HCV replication level was a gateway to the establishment of high replicative subgenomic replicons 72 that paved the way for drug discovery and testing 73,74 …”

Section: Research Tools For Studying Hcv‐genotypementioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus genotype 4: A poorly characterized endemic genotype

Leumi

Kassas

Zhong

2021

Journal of Medical Virology

View full text Add to dashboard Cite

Globally, 13% of all hepatitis C virus (HCV) infections are caused by genotype 4 (GT4), which consists of 17 subtypes with various levels of susceptibility to anti-HCV therapy.This genotype is endemic in the Middle East and Africa and has considerably spread to Europe lately. The molecular features of HCV-GT4 infection, as well as its appropriate therapeutics, are poorly characterized as it has not been the subject of widespread basic research. As such, in this review, we aim to gather the current state of knowledge of this genotype with a particular emphasis on its heterogeneity, sequence signatures, resistance-associated substitutions, and available in vivo and in vitro models used for its study. We urge developing more cell-culture models based on different GT4 subtypes to better understand the virology and therapeutic response of this particular genotype. This review may raise more awareness about this genotype and trigger more basic research work to develop its research tools. This will be critical to design better therapeutics and help to provide adequate guidelines for physicians working with HCV-GT4 patients.

show abstract

Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award

Cited by 4 publications

References 42 publications

Public funding for transformative drugs: the case of sofosbuvir

Public funding for transformative drugs: the case of sofosbuvir

Analysis of articles on hepatitis C by scientific mapping: 1989-2022

Hepatitis C virus genotype 4: A poorly characterized endemic genotype

Contact Info

Product

Resources

About